Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey A Silverman

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Blood|September 15, 2022
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 studyLuke Maese, Mignon L Loh, Mi Rim Choi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 10, 2018
Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical DevelopmentJim Zheng, Yan Xin, Jingyu Zhang, et al.
British Journal of Haematology|June 28, 2013
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomasFredrick Hagemeister, Maria Alma Rodriguez, Steven R Deitcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedulesRanjana H Advani, Herbert I Hurwitz, Michael S Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2018
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I StudyManish A Shah, Alexander Starodub, Sunil Sharma, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2010
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonistsMin Zhong, Emily J Hanan, Wang Shen, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry EyeMin Zhong, Thomas R Gadek, Minna Bui, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
Water-soluble prodrugs of an Aurora kinase inhibitorJohan D Oslob, Stacey A Heumann, Chul H Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemiaSusan O'Brien, Gary Schiller, John Lister, et al.
Cancer Chemotherapy and Pharmacology|August 4, 2009
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivoJennifer P Arbitrario, Brian J Belmont, Marc J Evanchik, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Blood|September 15, 2022
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 studyLuke Maese, Mignon L Loh, Mi Rim Choi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 10, 2018
Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical DevelopmentJim Zheng, Yan Xin, Jingyu Zhang, et al.
British Journal of Haematology|June 28, 2013
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomasFredrick Hagemeister, Maria Alma Rodriguez, Steven R Deitcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedulesRanjana H Advani, Herbert I Hurwitz, Michael S Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2018
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I StudyManish A Shah, Alexander Starodub, Sunil Sharma, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2010
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonistsMin Zhong, Emily J Hanan, Wang Shen, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry EyeMin Zhong, Thomas R Gadek, Minna Bui, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
Water-soluble prodrugs of an Aurora kinase inhibitorJohan D Oslob, Stacey A Heumann, Chul H Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemiaSusan O'Brien, Gary Schiller, John Lister, et al.
Cancer Chemotherapy and Pharmacology|August 4, 2009
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivoJennifer P Arbitrario, Brian J Belmont, Marc J Evanchik, et al.
Pageof 4